These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 24447269

  • 21. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study.
    Marcén R, Chahin J, Alarcón A, Bravo J.
    Transplant Proc; 2006 Oct; 38(8):2427-30. PubMed ID: 17097957
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

  • 23. Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus.
    Lauzurica R, Pastor MC, Bayes B, Malumbres S, Homs M, Llopis MA, Bonet J, Romero R.
    Transplant Proc; 2007 Sep; 39(7):2170-2. PubMed ID: 17889127
    [Abstract] [Full Text] [Related]

  • 24. Anorexia nervosa in a pediatric renal transplant recipient and its reversal with cyclosporine.
    Okechuku G, Boulos AK, Herman L, Upadhyay K.
    Pediatr Transplant; 2015 May; 19(3):E78-82. PubMed ID: 25661468
    [Abstract] [Full Text] [Related]

  • 25. Effect of calcineurin inhibitors on low-density lipoprotein oxidation.
    Cofan F, Cofan M, Campos B, Guerra R, Campistol JM, Oppenheimer F.
    Transplant Proc; 2005 Nov; 37(9):3791-3. PubMed ID: 16386540
    [Abstract] [Full Text] [Related]

  • 26. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients.
    Kim SJ, Prasad GV, Huang M, Nash MM, Famure O, Park J, Thenganatt MA, Chowdhury N, Cole EH, Fenton SS, Cattran DC, Zaltzman JS, Cardella CJ.
    Transplantation; 2006 Oct 15; 82(7):924-30. PubMed ID: 17038908
    [Abstract] [Full Text] [Related]

  • 27. Effects of immunosuppressive drugs on platelet aggregation and soluble P-selectin levels in renal transplant patients.
    Sahin G, Akay OM, Kus E, Bal C, Yalcin AU, Gulbas Z.
    Ren Fail; 2009 Oct 15; 31(2):111-7. PubMed ID: 19212907
    [Abstract] [Full Text] [Related]

  • 28. Two Decades of Tacrolimus in Renal Transplant: Basic Science and Clinical Evidences.
    Shrestha BM.
    Exp Clin Transplant; 2017 Feb 15; 15(1):1-9. PubMed ID: 27938316
    [Abstract] [Full Text] [Related]

  • 29. Neither cyclosporine nor tacrolimus deteriorate endothelial function in renal transplant recipients assessed with reactive hyperernia index.
    Grabczewska Z, Obońska K, Adamowicz A, Kasprzak M, Włodarczyk Z, Kubica J.
    Transplant Proc; 2013 May 15; 45(4):1567-70. PubMed ID: 23726621
    [Abstract] [Full Text] [Related]

  • 30. Impact of Conversion From Cyclosporine to Tacrolimus on Glucose Metabolism and Cardiovascular Risk Profiles in Long-Term Stable Kidney Transplant Recipients.
    Lim JH, Hwang I, Cho JH, Kwon E, Jung HY, Choi JY, Park SH, Kim YL, Kim HK, Huh S, Won DI, Kim CD.
    Transplant Proc; 2019 Oct 15; 51(8):2697-2703. PubMed ID: 31439330
    [Abstract] [Full Text] [Related]

  • 31. [Metabolic disorders in renal transplant recipients].
    Mikolasević I, Jelić I, Sladoje-Martinović B, Orlić L, Zivcić-Cosić S, Vuksanović-Mikulicić S, Mijić M, Racki S.
    Acta Med Croatica; 2012 Jul 15; 66(3):235-41. PubMed ID: 23441539
    [Abstract] [Full Text] [Related]

  • 32. Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients.
    Sessa A, Esposito A, Giliberti A, Iavicoli G, Costa C, Bergallo M, Lettieri E, Rossano R, Capuano M.
    Transplant Proc; 2009 May 15; 41(4):1178-82. PubMed ID: 19460510
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Cyclosporine nephrotoxicity and early posttransplant hyperkalemia in living-donor renal recipients: report of 4 cases.
    Pavleska-Kuzmanovska S, Popov Z, Ivanovski O, Ristovska V, Masin-Spasovska J, Rambabova-Busljetic I, Ivanovski N.
    Exp Clin Transplant; 2014 Oct 15; 12(5):479-83. PubMed ID: 24417207
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 15; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 39. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease.
    Sztanek F, Seres I, Harangi M, Lőcsey L, Padra J, Paragh GJ, Asztalos L, Paragh G.
    Nephrol Dial Transplant; 2012 Jul 15; 27(7):2866-72. PubMed ID: 22247228
    [Abstract] [Full Text] [Related]

  • 40. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation.
    Marcén R, Galeano C, Fernández-Rodriguez A, Jiménez-Alvaro S, Teruel JL, Rivera M, Burgos FJ, Quereda C.
    Transplant Proc; 2010 Oct 15; 42(8):3055-7. PubMed ID: 20970609
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.